Veraflox
pradofloxacin
Table of contents
Overview
This is a summary of the European public assessment report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP), on the basis of the documentation provided, led to the recommendations on the conditions of use.
This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Authorisation details
Product details | |
---|---|
Name |
Veraflox
|
Agency product number |
EMEA/V/C/000159
|
Active substance |
pradofloxacin
|
International non-proprietary name (INN) or common name |
pradofloxacin
|
Species |
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QJ01MA97
|
Publication details | |
---|---|
Marketing-authorisation holder |
Bayer Animal Health GmbH
|
Revision |
8
|
Date of issue of marketing authorisation valid throughout the European Union |
12/04/2011
|
Contact address |
Bayer Animal Health GmbH
D-51368 Leverkusen Germany |
Product information
31/03/2020 Veraflox - EMEA/V/C/000159 - IG/1213
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Antibacterials for systemic use
-
Fluoroquinolones
Therapeutic indication
Dogs
Treatment of:
- wound infections caused by susceptible strains of the Staphylococcus intermedius group (including S. pseudintermedius);
- superficial and deep pyoderma caused by susceptible strains of the Staphylococcus intermedius group (including S. pseudintermedius);
- acute urinary-tract infections caused by susceptible strains of Escherichia coli and the Staphylococcus intermedius group (including S. pseudintermedius);
- as adjunctive treatment to mechanical or surgical periodontal therapy in the treatment of severe infections of the gingiva and periodontal tissues caused by susceptible strains of anaerobic organisms, for example Porphyromonas spp. and Prevotella spp.
Treatment of acute infections of the upper respiratory tract caused by susceptible strains of Pasteurella multocida, Escherichia coli and the Staphylococcus intermedius group (including S. pseudintermedius).